source
- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is…Endpoints · 3mo ago↗ source
- Bristol Myers’ pivotal year; Should AI be swinging bigger?; and moreWelcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-brea…Endpoints · 3mo ago↗ source
- Arvinas’ ‘Protac’ breast cancer drug cleared by FDAKnown as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.BioPharma Dive